Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1549 : YSCCC  update : 2022/07/07
CommentHuman cell line derived from cholangiocellular carcinoma.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Imanishi, Hiroyasu
Originator Imanishi, Hiroyasu
Year of deposit 1999
Another name CCC
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 70 years
Tissue liver, ascites meta
Disease name cholangiocellular carcinoma
Metastastatic ability Yes
Metastatsd tissue ascites
Classification cancer
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_3629
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Chromosome mode 65-73(50) : /67(5),68(8),69(10),70(11),71(8),72(4)/
STR(human) OK
deposit info
lot info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
10,12 12 10, 11 10, 11 16, 17 7, 9 X 11 10, 11
Images
deposit info
lot info
Reference information Reference 0
User's Publication 9


To topTop
Reference

To topTop
User's Publication
13485  Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.  Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes  Cancer Sci  2021  112(2):828-838  PubMed ID: 33345417   DOI: 10.1111/cas.14780
16101  Nattawan Suwannakul, Napat Armartmuntree, Raynoo Thanan, Kaoru Midorikawa, Tetsuo Kon, Shinji Oikawa, Hatasu Kobayashi, Ning Ma, Shosuke Kawanishi, Mariko Murata  Targeting fructose metabolism by glucose transporter 5 regulation in human cholangiocarcinoma  Genes & Diseases  2021      DOI: 10.1016/j.gendis.2021.09.002
10658  Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.  Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.  Oncol. Rep.  2018  39:843-850  PubMed ID: 29251327   DOI: 10.3892/or.2017.6153
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
3709  Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, Ariizumi S, Yamamoto M, Kurosaki K, Shoda J.  Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.  J Gastroenterol  2015  50(4):467-79  PubMed ID: 25112701   DOI: 10.1007/s00535-014-0984-5
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941   DOI: 10.1007/s00534-011-0376-7
7938  Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.  Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.  J. Gastroenterol.  2011  46:779-89  PubMed ID: 21331764   DOI: 10.1007/s00535-011-0380-3
13665  Kamigaki M, Sasaki T, Serikawa M, Inoue M, Kobayashi K, Itsuki H, Minami T, Yukutake M, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Chayama K.  Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells  Int J Oncol  2011  39(3):561-8  PubMed ID: 21687941   DOI: 10.3892/ijo.2011.1087



Back Back Return Top Page